Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How CABA compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -297.5% | +428.9 pp | +901.1 pp | |
| LTM Mar 2026 | -345.5% | -170.5 pp | +1537.1 pp | |
| FY2025 | -2506.5% | -213.2 pp | +17413.5 pp | |
| LTM Mar 2026 | -5649.2% | -4216.0 pp | +132.7 pp | |
| LTM Mar 2026 | -618909.7% | -64222.0 pp | -565818.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding CABA) | -2506.5% | -213.2 pp | +901.1 pp | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.